Evidence map›Paper›PMID 38460949›Full record

ArticleNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2024

Sex differences in cancer outcomes across the range of eGFR.

Richard Shemilt, Michael K Sullivan, Peter Hanlon, Bhautesh D Jani, Nicole De La Mata, Brenda Rosales, Benjamin M P Elyan, James A Hedley, Rachel B Cutting, Melanie Wyld and 4 more

Erratum issuedOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Richard ShemiltNHS Greater Glasgow and Clyde, G12 0XH, UK.ORCID 0000-0002-5498-5154
Michael K SullivanNHS Greater Glasgow and Clyde, G12 0XH, UK.ORCID 0000-0002-3800-2330
Peter HanlonSchool of Health and Wellbeing, University of Glasgow, Glasgow G12 8TB, UK.ORCID 0000-0002-5828-3934
Bhautesh D JaniSchool of Health and Wellbeing, University of Glasgow, Glasgow G12 8TB, UK.ORCID 0000-0001-7348-514X
Nicole De La MataSydney School of Public Health, University of Sydney, Sydney NSW 2050, Australia.ORCID 0000-0001-7739-3656
Brenda RosalesSydney School of Public Health, University of Sydney, Sydney NSW 2050, Australia.
Benjamin M P ElyanNHS Greater Glasgow and Clyde, G12 0XH, UK.
James A HedleySydney School of Public Health, University of Sydney, Sydney NSW 2050, Australia.ORCID 0000-0002-6077-0862
Rachel B CuttingSydney School of Public Health, University of Sydney, Sydney NSW 2050, Australia.
Melanie WyldSydney School of Public Health, University of Sydney, Sydney NSW 2050, Australia.ORCID 0000-0001-9250-107X
David A McAllisterSchool of Health and Wellbeing, University of Glasgow, Glasgow G12 8TB, UK.
Angela C WebsterSydney School of Public Health, University of Sydney, Sydney NSW 2050, Australia.
Patrick B MarkNHS Greater Glasgow and Clyde, G12 0XH, UK.ORCID 0000-0003-3387-2123
Jennifer S LeesNHS Greater Glasgow and Clyde, G12 0XH, UK.ORCID 0000-0001-6331-0178
The University of Sydney · AUNHS Greater Glasgow and Clyde · GBUniversity of Glasgow · GB

Funding

Chief Scientist Office PCL/20/10University of Glasgow Office of Global Engagement Collaboration Partnership Award 9241562498University of SydneyWellcome TrustWellcome Trust 301005/Z/23/Z
6 · The paper itself

Abstract

backgroundPeople with chronic kidney disease (CKD) have increased incidence and mortality of most cancer types. We hypothesized that the odds of presenting with advanced cancer may vary according to differences in estimated glomerular filtration rate (eGFR), that this could contribute to increased all-cause mortality and that sex differences may exist.

methodsData were from Secure Anonymised Information Linkage Databank, including people with de novo cancer diagnosis (2011-17) and two kidney function tests within 2 years prior to diagnosis to determine baseline eGFR (mL/min/1.73 m2). Logistic regression models determined the odds of presenting with advanced cancer by baseline eGFR. Cox proportional hazards models tested associations between baseline eGFRCr and all-cause mortality.

resultseGFR <30 was associated with higher odds of presenting with advanced cancer of prostate, breast and female genital organs, but not other cancer sites. Compared with eGFR >75-90, eGFR <30 was associated with greater hazards of all-cause mortality in both sexes, but the association was stronger in females [female: hazard ratio (HR) 1.71, 95% confidence interval (CI) 1.56-1.88; male versus female comparison: HR 0.88, 95% CI 0.78-0.99].

conclusionsLower or higher eGFR was not associated with substantially higher odds of presenting with advanced cancer across most cancer sites, but was associated with reduced survival. A stronger association with all-cause mortality in females compared with males with eGFR <30 is concerning and warrants further scrutiny.

Indexed as

Glomerular Filtration RateNeoplasmsRenal Insufficiency, ChronicAgedCause of DeathFemaleFollow-Up StudiesHumansIncidenceKidney Function TestsMaleMiddle AgedPrognosisRisk FactorsSex FactorsSurvival Ratecancerchronic kidney diseasecohort studiesfemalemale

Identifiers

PMID38460949
PMCPMC11648947
OpenAlexW4392627728

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.